ORG Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

ORG Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-22	Closed	-$466	–	1607
2025 Q2	$466	Hold	22	–	–	﹤0.01%	1421
2025 Q1	$526	Buy	+22	New	+$495	﹤0.01%	1268

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ORG Partners's CPRX Position: Q3 2025 in Review

ORG Partners sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 22 shares — an estimated $466 sold.

ORG Partners first reported a position in CPRX in Q1 2025 and held it in 2 quarters. The position peaked at $526 in Q1 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

ORG Partners reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
ORG Partners sold 22 Catalyst Pharmaceutical shares in Q3 2025, an estimated $466.
ORG Partners first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 2 quarters.
ORG Partners's Catalyst Pharmaceutical position peaked at $526 in Q1 2025.
360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on ORG Partners's 13F filing for Q3 2025, filed 24 Oct 2025.